Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: Potential pharmacotherapies for the treatment of psychostimulant abuse

Current Topics in Medicinal Chemistry

Volumn 11, Issue 9, 2011, Pages 1103-1127

  Crooks, Peter A ^a   Zheng, Guangrong ^a   Vartak, Ashish P ^a   Culver, John P ^a   Zheng, Fang ^a   Horton, David B ^a   Dwoskin, Linda P ^a  

^a University of Kentucky   (United States)

Author keywords

Computational modeling; Lobeline; Lobeline analogs; Psychostimulant abuse; Vesicular monoamine transporter 2 (VMAT2)

Indexed keywords

ETHYLENE; HYDROXYL GROUP; KETONE; LIGAND; LOBELINE; METHYL GROUP; PIPERIDINE; PYRROLIDINE DERIVATIVE; TROPANE DERIVATIVE; VESICULAR MONOAMINE TRANSPORTER 2;

ARTICLE; ARTIFICIAL NEURAL NETWORK; BINDING AFFINITY; DRUG ABUSE; DRUG DEPENDENCE; DRUG DESIGN; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; ISOMERIZATION; NONHUMAN; PREDICTIVE VALUE; PROTEIN STRUCTURE; STRUCTURE ANALYSIS;

ANIMALS; BEHAVIOR, ADDICTIVE; BINDING SITES; DRUG DESIGN; DRUG THERAPY; HUMANS; LIBRARIES, DIGITAL; LIGANDS; LOBELIA; LOBELINE; MICE; MOLECULAR TARGETED THERAPY; NEURAL NETWORKS (COMPUTER); NEURONS; PSYCHOTROPIC DRUGS; RATS; RECEPTORS, NICOTINIC; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTANCE-RELATED DISORDERS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 79954513618     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802611795371332     Document Type: Article

References (108)

1. Erickson, J. D.; Schafer, M. K.; Bonner, T. I.; Eiden, L. E.; Weihe E. Distinct pharmacological properties and distribution in neurons and endocrine cells of isoforms of the human vesicular monoamine transporter. Proc. Natl. Acad. Sci., 1996, 93, 5166-5171.
2. Erickson, J. D.; Eiden, L. Functional identification and molecular cloning of a human brain vesicle monoamine transporter. J. Neurochem., 1993, 61, 2314-2317.
3. Erickson, J. D.; Eiden, L. E; Hoffman, B. J. Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc. Natl. Acad. Sci., 1992, 89, 10993-10997.
4. Zheng, G.; Dwoskin, L. P.; Crooks, P. A. Vesicular monoamine transporter-2: Role as a novel target for drug development. AAPS J., 2006, 4(8), E682-E692.
5. Peter, D.; Jimenez, J.; Liu, Y.; Kim, J.; Edwards, R. H. The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors. J. Biol. Chem., 1994, 269, 7231-7237.
6. Peter, D.; Liu Y.; Sternini, C.; de Giorgio, R.; Brecha, N.; Edwards, R. H. Differential expression of two vesicular monoamine transporters. J. Neurosci., 1995, 15, 6179-6188.
7. Weihe, E., Schafer M. K.; Erickson J. D.; Eiden L. E. al. Localization of vesicular monoamine transporter isoforms (VMAT1 and VMAT2) to endocrine cells and neurons in rat. J. Mol. Neurosci., 1994, 5, 149-164.
8. Krejci, E.; Gasnier, B.; Botton, D.; Isambert, M.F.; Sagné, C.; Gagnon, J.; Massoulié, J.; Henry, J.P. Expression and regulation of the bovine vesicular monoamine transporter gene. FEBS Lett., 1993, 335, 27-32.
9. Stern-Bach, Y.; Keen, J. N.; Bejerano, M.; Steiner-Mordoch, S.; Wallach, M.; Findlay, J. B.; Schuldiner, S. Homology of a vesicular amine transporter to a gene conferring resistance to 1-methyl-4-phenylpyridinium. Proc. Natl. Acad. Sci. USA, 1992, 89, 9730-9733.
10. Howell, M.; Shirvan, A.; Stern-Bach, Y.; Steiner-Mordoch, S.; Strasser, J.E.; Dean, G.E.; Schuldiner, SCloning and functional expression of a tetrabenazine sensitive vesicular monoamine transporter from bovine chromaffin granules. FEBS Lett., 1994, 338, 16-22.
11. Lohoff, F. W.; Dahl, J. P.; Ferraro, T. N.; Arnold, S. E.; Gallinat, J.; Sander, T.; Berrettini, W. H. Variations in the vesicular monoamine transporter 1 gene (VMAT1/SLC18A1) are associated with bipolar I disorder. Neuropsychopharmacology, 2006, 31, 2739-2747.
12. Hansson, S. R.; Mezey, E; Hoffman, B. J. Ontogeny of vesicular monoamine transporter mRNAs VMAT1 and VMAT2, II. Expression in neural crest derivatives and their target sites in the rat. Dev. Brain Res., 1998, 110, 159-174.
13. Pletscher, A. Effect of neuroleptics and other drugs on monoamine uptake by membranes of adrenal chromaffin granules. Br. J. Pharmacol., 1977, 59, 419-424.
14. Darchen, F.; Scherman, D; Henry, J. P. Reserpine binding to bovine chromaffin granule membranes. Mol. Pharmacol., 1984, 25, 113-122.
15. Scherman, D.; Henry, J. P. Radioligands of the vesicular monoamine transporter and their use as markers of monoamine storage vesicles. Biochem. Pharmacol., 1989, 38, 2395-2404.
16. Henry, J. P.; Scherman, D. Radioligands of the vesicular monoamine transporter and their use as markers of monoamine storage vesicles. Biochem. Pharmacol., 1989, 38, 2395-2404.
17. 3H]dihydrotetrabenazine. Proc. Natl. Acad. Sci. USA, 1983, 80, 584-588.
18. Amara, S. G.; Sonders, M. S. Neurotransmitter transporters as molecular targets for addictive drugs. Drug Alcohol Depend., 1998, 51, 87-96.
19. Wise, R. A.; Bozarth, M. A. A psychostimulant theory of addiction. Psychol. Rev., 1987, 94, 469-492.
20. Koob, G. F. Neural mechanisms of drug reinforcement. Ann. N Y Acad. Sci., 1992, 654, 171-191.
21. Fleckenstein, A. E.; Hanson, G. R. Impact of psychostimulants on vesicular monoamine transporter function. Eur. J. Pharmacol., 2003, 479, 283-289.
22. Riddle, E. L.; Fleckenstein, A. E.; Hanson, G. R. Role of monoamine transporters in mediating psychostimulant effects. AAPS J., 2005, 7, E847-E851.
23. Brown, J. M.; Hanson, G. R.; Fleckenstein, A. E. Regulation of the vesicular monoamine transporter-2: A novel mechanism for cocaine and other psychostimulants. J. Pharmacol. Exp. Ther., 2001, 296, 762-767.
24. Sulzer, D.; Maidment, N. T.; Rayport, S. Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons. J. Neurochem., 1993, 60, 527-535.
25. Sulzer, D.; Chem, T. K.; Lau, Y. Y.; Kristensen, H.; Rayport, S.; Ewing, A. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci., 1995, 15, 4102-4108.
26. Johnson, R. G. Accumulation of biological amines into chromaffin granules: A model for hormone and neurotransmitter transport. Physiol. Rev., 1988, 68, 232-307.
27. Sulzer, D.; Rayport, S. Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: A mechanism of action. Neuron., 1990, 5, 797-808.
28. Takahashi, N.; Miner, L. L.; Sora, I.; Ujike, H.; Revay, R.S.; Kostic, V.; Jackson-Lewis, V.; Przedborski, S.; Uhl, G.R. VMAT2 knockout mice: heterozygotes display reduced amphetamineconditioned reward, enhanced amphetamine locomotion and enhanced MPTP toxicity. Proc. Natl. Acad. Sci. USA, 1997, 94, 9938-9943.
29. Wang, Y.; Gainetdinov, R. R.; Fumagalli, F.; Xu, F.; Jones, S. R.; Bock, C. B.; Miller, G. W.; Wightman, R. M.; Caron, M. G. Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron, 1997, 19, 1285-1296.
30. Dwoskin, L. P.; Crooks, P. A. A Novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse. Biochem. Pharmacol., 2002, 63, 89-98.
31. Peter, D.; Vu, T.; Edwards, R. H. Chimeric vesicular monoamine transporters identify structural domains that influence substrate affinity and sensitivity to tetrabenazine. J. Biol. Chem., 1996, 271, 2979-2986.
32. nd Ed. Reith, M.; Humana Press, Totowa, 2002, 313-354.
33. Merickel, A.; Rosandich, P.; Peter, D.; Edwards, R. H. Identification of residues involved in substrate recognition by a vesicular monoamine transporter. J. Biol. Chem., 1995, 270, 25798-25804.
34. Merickel, A.; Kaback, H. R.; Edwards, R. H. Charged residues in transmembrane domains II and XI of a vesicular monoamine transporter form a chard pair that promotes high affinity substrate recognition. J. Biol. Chem., 1997, 272, 5403-5408.
35. 125I]2-N-[(3'-iodo-4'-azidophenyl) propionyl]tetrabenazine binding sites for the synaptic vesicle monoamine transporter. J. Biol. Chem., 1997, 272, 26049-26055.
36. Thiriot, D. S.; Ruoho, A. E. Mutagenesis and deriviatization of human vesicle monoamine transporter 2 (VMAT2) cysteines identifies transporter domains involved in tetrabenazine binding and substrate transport. J. Biol. Chem., 2001, 276, 27304-27315.
37. Vardy, E.; Arkin, I. T.; Gottschalk, K. E.; Kaback, H. R.; Schuldiner, S. Structural conservation in the major facilitator superfamily as revealed by comparative modeling. Protein Sci., 2004, 13, 1982-1840.
38. Gros, Y.; Schuldiner, S. Directed evolution reveals hidden properties of VMAT, a neurotransmitter transporter. J. Biol. Chem., 2010, 285, 5076-5084.
39. Millspaugh, C. F. Lobelia Inflata In: American Medicinal Plants: An Illustrated and Descriptive Guide to Plants Indigenous to and Naturalized in the United States Which Are Used in Medicine; Dover: New York, 1974, pp. 385-388.
40. Felpin, F. X.; Lebreton, J. History, chemistry and biology of alkaloids from Lobelia inflata. Tetrahedron, 2004, 60, 10127-10153.
41. Wieland, H. Alkaloids of the Lobelia plant. I. (Preliminary Communication.). Ber. Dtsch. Chem. Ges., 1921, 54B, 1784-1788.
42. Wieland, H.; Schopf, C.; Hermsen, W. Lobelia Alkaloids. Ii. Liebigs Ann. Chem., 1925, 444, 40-68.
43. Wieland, H.; Dragendorff, O. Lobelia alkaloids. Iii. Constitution of the Lobelia alkaloids. Liebigs Ann. Chem., 1929, 473, 83-101.
44. Wieland, H.; Drishaus, I. Lobelia Alkaloids. Iv. Synthesis of Lobelia alkaloids. Liebigs Ann. Chem., 1929, 473, 102-118.
45. Wieland, H.; Koschara, W.; Dane, E. Lobelia alkaloids. V. Several bases accompanying lobeline and the reciprocal relations of the Lobelia alkaloids. Liebigs Ann. Chem., 1929, 473, 118-126.
46. Scheuing, G.; Winterhalder, L. Synthesis of Lobelia alkaloids. Justus Liebigs Ann. Chem., 1929, 473, 126-136.
47. Schopf, C.; Lehmann, G. Syntheses and transformations of natural products under physiological conditions (model experiments on the question of the biogenesis of natural products). Iv. Syntheses of tropinone, pseudopelletierine, lobelanine and related qlkaloids under physiological conditions. Liebigs Ann. Chem., 1935, 518, 1-37.
48. Schoepf, C.; Mueller, E. Absolute configuration of (-)-lobeline and of its reduction products. Liebigs Ann. Chem., 1965, 687, 241-250.
49. Compere, D.; Marazano, C.; Das, B. C. Enantioselective access to Lobelia alkaloids. J. Org. Chem., 1999, 64, 4528-4532.
50. Felpin, F.-X.; Lebreton, J. A highly stereoselective asymmetric synthesis of (-)-lobeline and (-)-sedamine. J. Org. Chem., 2002, 67, 9192-9199.
51. Klingler, F.-D.; Sobotta, R. (Boehringer Ingelheim Pharma Gmbh & Co. KG, Germany, US, 2006, p. 4.
52. Birman, V. B.; Jiang, H.; Li, X. Enantioselective synthesis of lobeline via nonenzymatic desymmetrization. Org. Lett., 2007, 9, 3237-3240.
53. Zheng, G.; Dwoskin, L. P.; Crooks, P. A. Indirect trapping of the retroconjugate addition reaction intermediate involved in the epimerization of lobeline: Application to the synthesis of (-)-sedamine. J. Org. Chem., 2004, 69, 8514-8517.
54. Vazquez, E.; Galindo, A.; Gnecco, D.; Bernes, S.; Teran, J. L.; Enriquez, R. G. Unexpected retro-Michael reaction of (-)-(1's,4as,8ar)-and (+)-(1's,4ar,8as)-4a-ethyl-1-(1-phenylethyl)octahydroquinolin-7-ones. Tetrahedron: Asymm., 2001, 12, 3209-3211.
55. Davis, F. A.; Zhang, J.; Li, Y.; Xu, H.; DeBrosse, C. Asymmetric synthesis of 2,4,5-trisubstituted piperidines from sulfiniminederived D-amino B-ketoesters. formal synthesis of pseudodistomin B triacetate. J. Org. Chem., 2005, 70, 5413-5419.
56. McCurdy, C. R.; Miller, R. L.; Beach, J. W. Lobeline: A natural product with high affinity for neuronal nicotinic receptors and a vast potential for use in neurological disorders. Biolog. Active Nat. Prod., 2000, 151-162.
57. Court, J. A.; Perry, E. K.; Spurden, D.; Lloyd, S.; Gillespie, J. I.; Whiting, P.; Barlow, R. Comparison of the binding of nicotinic agonists to receptors from human and rat cerebral cortex and from chick brain (alpha(4)beta(2) transfected into mouse fibroblasts with ion-channel activity. Brain Res., 1994, 667, 118-122.
58. Damaj, M. I.; Patrick, G. S.; Creasy, K. R.; Martin, B. R. Pharmacology of lobeline, a nicotinic receptor ligand. J. Pharmacol. Exp. Ther., 1997, 282, 410-419.
59. Flammia, D.; Dukat, M.; Damaj, M. I.; Martin, B.; Glennon, R. A. Lobeline: Structure-affinity investigation of nicotinic acetylcholinergic receptor binding. J. Med. Chem., 1999, 42, 3726-3731.
60. Miller, D. K.; Crooks, P. A.; Zheng, G. R.; Grinevich, V. P.; Norrholm, S. D.; Dwoskin, L. P. Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters. J Pharmacol. Exp. Ther., 2004, 310, 1035-1045.
61. Korczyn, A. D.; Bruderma. I.; Braun, K. Cardiovascular effects of lobeline. Arch. Int. Pharmacodyn. Ther., 1969, 182, 370-375.
62. Bevan, J. A.; Hughes, T. Inhibition of gastric contraction following stimulation of intrathoracic sensory endings. Arch. Int. Pharmacodyn. Ther., 1966, 161, 334-342.
63. Brioni, J. D.; Oneill, A. B.; Kim, D. J. B.; Decker, M. W. Nicotinic receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze test. Eur. J. Pharmacol., 1993, 238, 1-8.
64. Decker, M. W.; Majchrzak, M. J.; Arneric, S. P. Effects of lobeline, a nicotinic receptor agonist, on learning and memory. Pharmacol. Biochem. Behav., 1993, 45, 571-576.
65. Hamann, S. R.; Martin, W. R. Hyperalgesic and analgesic actions of morphine, U50-488, naltrexone, and (-)-lobeline in the rat brainstem. Pharmacol. Biochem. Behav., 1994, 47, 197-201.
66. Barlow, R. B.; Johnson, O. Relations between structure and nicotine-like activity-Xray crystal-structure analysis of (-)-cytisine and (-)-lobeline hydrochloride and a comparison with (-)-nicotine and other nicotine-like compounds. Br. J. Pharmacol., 1989, 98, 799-808.
67. Rasmussen, T.; Swedberg, M. D. B. Reinforcing effects of nicotinic compounds: Intravenous self-administration in drug-naive mice. Pharmacol. Biochem. Behav., 1998, 60, 567-573.
68. Harrod, S. B.; Dwoskin, L. P.; Green, T. A.; Gehrke, B. J.; Bardo, M. T. Lobeline does not serve as a reinforcer in rats. Psychopharmacol., 2003, 165, 397-404.
69. Fudala, P. J.; Iwamoto, E. T. Further studies on nicotine-induced conditioned place preference in the rat. Pharmacol. Biochem. Behav., 1986, 25, 1041-1049.
70. Stolerman, I. P.; Garcha, H. S.; Mirza, N. R. Dissociations between the locomotor stimulant and depressant effects of nicotinic agonists in rats. Psychopharmacology, 1995, 117, 430-437.
71. Miller, D. K.; Harrod, S. B.; Green, T. A.; Wong, M. Y.; Bardo, M. T.; Dwoskin, L. P. Lobeline attenuates locomotor stimulation induced by repeated nicotine administration in rats. Pharmacol. Biochem. Behav., 2003, 74, 279-286.
72. (+) efflux from thalamic synaptosomes. Neuropharmacology, 2000, 39, 2654-2662.
73. Briggs, C. A.; McKenna, D. G. Activation and inhibition of the human alpha 7 nicotinic acetylcholine receptor by agonists. Neuropharmacology, 1998, 37, 1095-1102.
74. 3H]dopamine uptake. J. Pharmacol. Exp. Ther., 1997, 280, 1432-1444.
75. 3H]dopamine from rat striatal synaptic vesicles: Comparison with D-amphetamine. J. Neurochem., 1998, 71, 258-265.
76. Wilhelm, C. J.; Johnson, R. A.; Lysko, P. G.; Eshleman, A. J.; Janowsky, A. Effects of methamphetamine and lobeline on vesicular monoamine and dopamine transporter-mediated dopamine release in a cotransfected model system. J. Pharmacol. Exp. Ther., 2004, 310, 1142-1151.
77. Wilhelm, C. J.; Johnson, R. A.; Eshleman, A. J.; Janowsky, A. Lobeline effects on tonic and methamphetamine-induced dopamine release. Biochem. Pharmacol., 2008, 75, 1411-1415.
78. Miller, D. K.; Crooks, P. A.; Teng, L. H.; Witkin, J. M.; Munzar, P.; Goldberg, S. R.; Acri, J. B.; Dwoskin, L. P. Lobeline inhibits the neurochemical and behavioral effects of amphetamine. J. Pharmacol. Exper. Ther., 2001, 296, 1023-1034.
79. Harrod, S. B.; Dwoskin, L. P.; Crooks, P. A.; Klebaur, J. E.; Bardo, M. T. Lobeline attenuates D-methamphetamine self-administration in rats. J. Pharmacol. Exp. Ther., 2001, 298, 172-179.
80. Tatsuta, T.; Kitanaka, N.; Kitanaka, J.; Morita, Y.; Takemura, M. Lobeline attenuates methamphetamine-induced stereotypy in adolescent mice. Neurochem. Res., 2006, 31, 1359-1369.
81. Neugebauer, N. M.; Dwoskin, L. P.; Bardo, M. T. Lobeline attenuates cocaine self-administration in rats. Behav. Pharmacol., 2007, 18, S26-S26.
82. Polston, J. E.; Cunningham, C. S.; Rodvelt, K. R.; Miller, D. K. Lobeline augments and inhibits cocaine-induced hyperactivity in rats. Life Sci., 2006, 79, 981-990.
83. Eyerman, D. J.; Yamamoto, B. K. Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum. J. Pharmacol. Exp. Ther., 2005, 312, 160-169.
84. Miller, D. K.; Lever, J. R.; Rodvelt, K. R.; Baskett, J. A.; Will, M. J.; Kracke, G. R. Lobeline, a potential pharmacotherapy for drug addiction, binds to mu opioid receptors and diminishes the effects of opioid receptor agonists. Drug Alcohol Depend., 2007, 89, 282-291.
85. Ebnöther, A. Alkaloids. Ix. Mutarotation of lobeline. cis-trans isomers in the Lobelia alkaloid series. Helv. Chim. Acta, 1958, 41, 386-396.
86. Hojahmat, M.; Horton, D. B.; Norrholm, S. D.; Miller, D. K.; Grinevich, V. P.; Deaciuc, A. G.; Dwoskin, L. P.; Crooks, P. A. Lobeline esters as novel ligands for neuronal nicotinic acetylcholine receptors and neurotransmitter transporters. Bioorg. Med. Chem. Lett., 2010, 18, 640-649.
87. Zheng, G.; Horton, D. B.; Deaciuc, A. G.; Dwoskin, L. P.; Crooks, P. A. Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. Bioorg. Med. Chem. Lett., 2006, 16, 5018-5021.
88. Zheng, G.; Dwoskin, L. P.; Deaciuc, A. G.; Norrholm, S. D.; Crooks, P. A. Defunctionalized lobeline analogues: Structureactivity of novel ligands for the vesicular monoamine transporter. J. Med. Chem., 2005, 48, 5551-5560.
89. Zheng, G.; Dwoskin, L. P.; Deaciuc, A. G.; Zhu, J.; Jones, M. D.; Crooks, P. A. Lobelane analogues as novel ligands for the vesicular monoamine transporter-2. Bioorg. Med. Chem., 2005, 13, 3899-3909.
90. Neugebauer, N. M.; Harrod, S. B.; Stairs, D. J.; Crooks, P. A.; Dwoskin, L. P.; Bardo, M. T. Lobelane decreases methamphetamine self-administration in rats. Eur. J. Pharmacol., 2007, 571, 33-38.
91. Varkat, A.P.; Deaciuc, A.G.; Dwoskin, L.P.; Crooks, P.A. Quintobelane: a water-soluable lobelane analogue and inhibitor of VMAT2. Bioorg. Med. Chem. Lett., 2010, 20, 3584-3587.
92. Zheng, G.; Dwoskin, L. P.; Deaciuc, A. G.; Crooks, P. A. Synthesis and evaluation of a series of homologues of lobelane at the vesicular monoamine transporter-2. Bioorg. Med. Chem., 2008, 18, 6509-6512.
93. Katritzky, A. R.; Cui, X. L.; Yang, B.; Steel, P. J. Asymmetric syntheses of 2-substituted and 2,5-disubstituted pyrrolidines from (3s,5r,7ar)-5-(benzotriazol-1-Yl)-3-phenyl[2,1-B]oxazolopyrrolidine. J. Org. Chem., 1999, 64, 1979-1985.
94. Varkat, A. P.; Nickell, J. R.; Chagkutip, J.; Dwoskin, L. P.; Crooks, P. A. Pyrrolidine Analogs of lobeline: relationship of Affinity for the dihydrotetrabenazine binding site with function of the vesicular monoamine transporter (VMAT2). J. Med. Chem., 2009, 52, 7878-7882.
95. Zheng, G.; Dwoskin, L. P.; Deaciuc, A. G.; Crooks, P. A. Synthesis and evaluation of a series of tropane analogues as novel vesicular monoamine transporter-2 ligands. Bioorg. Med. Chem. Lett., 2005, 15, 4463-4466.
96. nd Ed.; McGraw-Hill: New York, 1991.
97. Sejnowski, T. J.; Rosenberg, C. R. Complex systems, 1987, 1, 145.
98. Shah, D. R.; Dev, V. R.; Brown, C. A. The utilization of a neural network system in the diagnosis of appendicitis. M. D. Comput: Comput. Med. Pract., 1999, 16, 65-67.
99. Seker, H.; Odetayo, M. O.; Petrovic, D.; Naguib, R. N. G.; Bartoli, C.; Alasio, L.; Lakshmi, M. S.; Sherbet, G. V. Assessment of nodal involvement and survival analysis in breast cancer patients using image cytometric data: statistical, neural network and fuzzy approaches. Anticancer Res., 2002, 22, 433-438.
100. Sardari, S.; Sardari, D. Applications of artificial neural networks in AIDS research and therapy. Curr. Pharm. Des., 2002, 8, 659-670.
101. Ochoa, C.; Chana A.; Stud, M. Applications of neural networks in the medicinal chemistry field. Curr. Med. Chem.-Central Nervous Syst. Agents, 2001, 1, 247-256.
102. Kaiser, K. L. E. Neural networks for effect prediction in environmental and health issues using large datasets. Quant. Struct. Act. Relat., 2003, 22, 1-6.
103. Zheng, F.; Bayram, E.; Sumithran, S. P.; Ayers, J. T.; Zhan, C.-G.; Schmitt, J. D.; Dwoskin, L. P.; Crooks, P. A. QSAR modeling of mono-and bis-quanternary ammonium salts that act as antagonists at neuronal nicotinic acetylcholine receptors mediating dopamine release. Bioorg. Med. Chem., 2006, 14, 3017-3037.
104. Katritzky, A. R., Pacureanu, L M.; Dobchev, D. A.; Fara, D. C.; Duchowicz, P. R.; Karelson, M. QSAR modeling of the inhibition of glycogen synthase kinase-3 Bioorg. Med. Chem., 2006, 14, 4987-5002.
105. Huuskonen, J.; Salo, M.; Taskinen, J. Neural network modeling for estimation of the aqueous solubility of structurally related drugs. J. Pharm. Sci., 1997, 86, 450-454.
106. Li, H.; Yap, C. W.; Xue, Y.; Li, Z. R.; Ung, C. Y.; Han, L. Y.; Chen, Y. Z. Statistical learning approach for predicting specific pharmacodynamic, pharmacokinetic, or toxicological properties of pharmaceutical agents. Drug Dev. Res., 2005, 66, 245-259.
107. Mager, D. E.; Shirey, J. D.; Cox, D.; Fitzgerald, D. J.; Abernethy, D. R. Mapping the dose-effect relationship of orbofiban from sparse data with an artificial neural network. J. Pharm. Sci., 2005, 94, 2475-2486.
108. Zheng, F.; Zheng, G. R.; Deaciuc, A. G.; Zhan, C.-G.; Dwoskin, L. P.; Crooks, P. A. Computational neural network analysis of the affinity of lobeline and tetrabenazine analogs for the vesicular monoamine transporter-2. Bioorg. Med. Chem., 2007, 15, 2975-2992